Abstract：
BACKGROUND: Cancer is a disease characterized by the abnormal multiplication of cells and is the second leading cause of death in the world. The search for new effective and safe anticancer compounds is ongoing due to factors such as low selectivity, high toxicity, and multidrug resistance. Thus, heterocyclic compounds derived from isatin, thiazole and phthalimide that have achieved promising in vitro anticancer activity have been tested in vivo and in clinical trials.
OBJECTIVE: This review focused on the compilation of promising data from thiazole, isatin, and phthalimide derivatives, reported in the literature between 2015 and 2022, with in vivo anticancer activity and clinical trials.
METHODS: A bibliographic search was carried out in the PUBMED, MEDLINE, ELSEVIER, and CAPES PERIODIC databases, selecting relevant works for each pharmacophoric group with in vivo antitumor activity in the last 6 years.
RESULTS: In our study, 68 articles that fit the scope were selected and critically analyzed. These articles were organized considering the type of antitumor activity and their year of publication. Some compounds reported here demonstrated potent antitumor activity against several tumor types.
CONCLUSIONS: This review allowed us to highlight works that reported promising structures for the treatment of various cancer types and also demonstrated that the privileged structures thiazole, isatin and phthalimide are important in the design of new syntheses and molecular optimization of compounds with antitumor activity.
OBJECTIVE: This review focused on the compilation of promising data from thiazole, isatin, and phthalimide derivatives, reported in the literature between 2015 and 2022, with in vivo anticancer activity and clinical trials.
METHODS: A bibliographic search was carried out in the PUBMED, MEDLINE, ELSEVIER, and CAPES PERIODIC databases, selecting relevant works for each pharmacophoric group with in vivo antitumor activity in the last 6 years.
RESULTS: In our study, 68 articles that fit the scope were selected and critically analyzed. These articles were organized considering the type of antitumor activity and their year of publication. Some compounds reported here demonstrated potent antitumor activity against several tumor types.
CONCLUSIONS: This review allowed us to highlight works that reported promising structures for the treatment of various cancer types and also demonstrated that the privileged structures thiazole, isatin and phthalimide are important in the design of new syntheses and molecular optimization of compounds with antitumor activity.
摘要：
背景：癌症是一种以细胞异常繁殖为特征的疾病，是世界上第二大死亡原因。由于选择性低等因素，寻找新的有效和安全的抗癌化合物正在进行中，高毒性,和多重耐药性。因此，源自Isatin的杂环化合物，已经在体内和临床试验中测试了已经获得有希望的体外抗癌活性的噻唑和邻苯二甲酰亚胺。
目的：这篇综述集中于噻唑，Isatin,和邻苯二甲酰亚胺衍生物，在2015年至2022年间的文献中报道，具有体内抗癌活性和临床试验。
方法：在PUBMED中进行了书目检索，MEDLINE,Elsevier,和CAPES周期性数据库，为最近6年具有体内抗肿瘤活性的每个药效组选择相关作品。
结果：在我们的研究中，选择了68篇符合该范围的文章，并进行了批判性分析。这些文章是考虑到抗肿瘤活性的类型及其发表年份而组织的。本文报道的一些化合物对几种肿瘤类型表现出有效的抗肿瘤活性。
结论：这篇综述使我们能够突出报道有希望的结构用于治疗各种癌症类型的作品，并证明了特级结构噻唑，在具有抗肿瘤活性的化合物的新合成设计和分子优化中，拉丁和邻苯二甲酰亚胺是重要的。
目的：这篇综述集中于噻唑，Isatin,和邻苯二甲酰亚胺衍生物，在2015年至2022年间的文献中报道，具有体内抗癌活性和临床试验。
方法：在PUBMED中进行了书目检索，MEDLINE,Elsevier,和CAPES周期性数据库，为最近6年具有体内抗肿瘤活性的每个药效组选择相关作品。
结果：在我们的研究中，选择了68篇符合该范围的文章，并进行了批判性分析。这些文章是考虑到抗肿瘤活性的类型及其发表年份而组织的。本文报道的一些化合物对几种肿瘤类型表现出有效的抗肿瘤活性。
结论：这篇综述使我们能够突出报道有希望的结构用于治疗各种癌症类型的作品，并证明了特级结构噻唑，在具有抗肿瘤活性的化合物的新合成设计和分子优化中，拉丁和邻苯二甲酰亚胺是重要的。
